PA
MRVI icon

Pinnacle Associates’s Maravai LifeSciences MRVI Stock Holding History

Pinnacle Associates’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,595
Closed -$69.4K – 870
2024
Q3 		$69.4K Buy
10,595
+370
+4% +$3.2K ﹤0.01% 787
2024
Q2 		$73.2K Hold
10,225
– – ﹤0.01% 799
2024
Q1 		$88.7K Sell
10,225
-370
-3% -$2.5K ﹤0.01% 818
2023
Q4 		$69.4K Buy
+10,595
New +$68.4K ﹤0.01% 801
2022
Q4 		– Sell
-68,600
Closed -$1.75M – 770
2022
Q3 		$1.75M Sell
68,600
-7,340
-10% -$184K 0.04% 307
2022
Q2 		$2.16M Sell
75,940
-2,465
-3% -$78.1K 0.05% 293
2022
Q1 		$2.77M Buy
+78,405
New +$2.63M 0.05% 291

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Pinnacle Associates's MRVI Position: Q4 2024 in Review

Pinnacle Associates sold out of Maravai LifeSciences (MRVI) in Q4 2024, closing a stake of 10,595 shares — an estimated $69.4K sold.

Pinnacle Associates first reported a position in MRVI in Q1 2022 and held it in 7 quarters. The position peaked at $2.77M in Q1 2022. 185 funds tracked by Wall St. Rank hold MRVI as of Q4 2024.

  • Pinnacle Associates reported no remaining Maravai LifeSciences position as of Q4 2024 after selling out during the quarter.
  • Pinnacle Associates sold 10,595 Maravai LifeSciences shares in Q4 2024, an estimated $69.4K.
  • Pinnacle Associates first reported a position in Maravai LifeSciences in Q1 2022 and held it in 7 quarters.
  • Pinnacle Associates's Maravai LifeSciences position peaked at $2.77M in Q1 2022.
  • 185 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2024.

Based on Pinnacle Associates's 13F filing for Q4 2024, filed 14 Feb 2025.